immunotherapy

• 

ASCO 2022: Sequencing of kidney cancer medicines

By Sharon Deveson Kell|2022-06-21T14:19:37+00:0021 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology (ASCO)  Annual Meeting [...]

Read More

Comments Off on ASCO 2022: Sequencing of kidney cancer medicines

• 

Sequencing of treatments for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-06-14T08:25:47+00:0014 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology Annual Meeting earlier [...]

Read More

Comments Off on Sequencing of treatments for advanced/metastatic kidney cancer

• 

Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

By Sharon Deveson Kell|2022-06-08T10:36:43+00:008 Jun 2022|Drug treatments|

Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]

Read More

Comments Off on Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

By Sharon Deveson Kell|2022-05-11T07:43:47+00:0011 May 2022|Drug treatments|

MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]

Read More

Comments Off on MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

• 

Treatment of local recurrence of kidney cancer after nephrectomy

By Sharon Deveson Kell|2022-05-11T07:22:04+00:0011 May 2022|Surgery|

Kidney cancer can come back after surgery to remove the [...]

Read More

Comments Off on Treatment of local recurrence of kidney cancer after nephrectomy

• 

EIKCS 2022: Debate about later-line treatments

By Sharon Deveson Kell|2022-04-25T13:44:50+00:0025 Apr 2022|Drug treatments|

At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]

Read More

Comments Off on EIKCS 2022: Debate about later-line treatments

• 

EIKCS 2022: Which is the best combination therapy?

By Sharon Deveson Kell|2022-04-25T13:45:22+00:0025 Apr 2022|Drug treatments|

During 2022 European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]

Read More

Comments Off on EIKCS 2022: Which is the best combination therapy?

• 

EIKCS 2022: Real world use of immunotherapy and survival in metastatic kidney cancer

By Sharon Deveson Kell|2022-04-25T13:45:48+00:0025 Apr 2022|Drug treatments, Uncategorized|

At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]

Read More

Comments Off on EIKCS 2022: Real world use of immunotherapy and survival in metastatic kidney cancer

• 

Sunitinib as a second-line treatment for advanced kidney cancer after combination immunotherapy

By Sharon Deveson Kell|2022-04-14T14:39:03+00:0014 Apr 2022|Drug treatments|

The results from a recent phase 2 trial looked at [...]

Read More

Comments Off on Sunitinib as a second-line treatment for advanced kidney cancer after combination immunotherapy